Granite Point Capital Management’s Summit Therapeutics SMMT Stock Holding History

Granite Point Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-150,000	Closed	-$1.81M	–	140
2018 Q1	$1.81M	Sell	150,000 -92,113	-38%	-$1.15M	0.17%	43
2017 Q4	$2.68M	Hold	242,113	–	–	0.26%	21
2017 Q3	$3.03M	Buy	242,113 +125,000	+107%	+$1.62M	0.64%	16
2017 Q2	$1.33M	Hold	117,113	–	–	0.33%	49
2017 Q1	$1.56M	Hold	117,113	–	–	0.47%	34
2016 Q4	$1M	Buy	117,113 +11,852	+11%	+$126K	0.8%	41
2016 Q3	$954K	Sell	105,261 -7,415	-7%	-$53.5K	0.37%	44
2016 Q2	$891K	Buy	+112,676	New	+$917K	0.38%	48
2015 Q4	$1.35M	Sell	117,841 -10,000	-8%	-$104K	0.2%	29
2015 Q3	$1.33M	Sell	127,841 -316	-0.2%	-$3.79K	0.91%	28
2015 Q2	$1.35M	Buy	128,157 +3,157	+3%	+$35.8K	0.39%	38
2015 Q1	$1.55M	Buy	+125,000	New	+$1.42M	0.57%	32

Other funds holding SMMT

LPU

Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Granite Point Capital Management's SMMT Position: Q2 2018 in Review

Granite Point Capital Management sold out of Summit Therapeutics (SMMT) in Q2 2018, closing a stake of 150,000 shares — an estimated $1.81M sold.

Granite Point Capital Management first reported a position in SMMT in Q1 2015 and held it in 12 quarters. The position peaked at $3.03M in Q3 2017. 17 funds tracked by Wall St. Rank hold SMMT as of Q2 2018.

Granite Point Capital Management reported no remaining Summit Therapeutics position as of Q2 2018 after selling out during the quarter.
Granite Point Capital Management sold 150,000 Summit Therapeutics shares in Q2 2018, an estimated $1.81M.
Granite Point Capital Management first reported a position in Summit Therapeutics in Q1 2015 and held it in 12 quarters.
Granite Point Capital Management's Summit Therapeutics position peaked at $3.03M in Q3 2017.
17 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2018.

Based on Granite Point Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.